NCT00088946View on ClinicalTrials.gov

Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions
Bladder Cancer
Interventions
DIETARY_SUPPLEMENT

Polyphenon E

4-200mg capsules PO daily for 12 months

DRUG

erlotinib hydrochloride

100 mg PO daily for 12 months

OTHER

Erlotinib placebo

identical to Erlotinib in look and appearance of dosing.

OTHER

Polyphenon E

identical to Polyphenon E in look and appearance of dosing.

Trial Locations (5)

55905

Mayo Clinic Cancer Center, Rochester

85032

Bladder Cancer Genitourinary Oncology, PC, Phoenix

90073

Veterans Affairs Medical Center - West Los Angeles, Los Angeles

90404

Santa Monica UCLA Medical Center, Santa Monica

90095-1781

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Jonsson Comprehensive Cancer Center

OTHER

NCT00088946 - Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer | Biotech Hunter | Biotech Hunter